DK0901466T3 - Biphenylsulfonamid-matriksmetalloproteinase-inhibitorer - Google Patents

Biphenylsulfonamid-matriksmetalloproteinase-inhibitorer

Info

Publication number
DK0901466T3
DK0901466T3 DK97918788T DK97918788T DK0901466T3 DK 0901466 T3 DK0901466 T3 DK 0901466T3 DK 97918788 T DK97918788 T DK 97918788T DK 97918788 T DK97918788 T DK 97918788T DK 0901466 T3 DK0901466 T3 DK 0901466T3
Authority
DK
Denmark
Prior art keywords
matriksmetalloproteinase
biphenylsulfonamide
inhibitors
alkyl
nhoh
Prior art date
Application number
DK97918788T
Other languages
Danish (da)
English (en)
Inventor
Patrick Michael O'brien
Drago Robert Sliskovic
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Application granted granted Critical
Publication of DK0901466T3 publication Critical patent/DK0901466T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/19Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/18Sulfonamides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/04Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/37Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C07C311/38Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton
    • C07C311/39Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/42Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
DK97918788T 1996-05-17 1997-04-24 Biphenylsulfonamid-matriksmetalloproteinase-inhibitorer DK0901466T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1746096P 1996-05-17 1996-05-17
PCT/US1997/006801 WO1997044315A1 (en) 1996-05-17 1997-04-24 Biphenylsulfonamide matrix metalloproteinase inhibitors

Publications (1)

Publication Number Publication Date
DK0901466T3 true DK0901466T3 (da) 2002-02-18

Family

ID=21782716

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97918788T DK0901466T3 (da) 1996-05-17 1997-04-24 Biphenylsulfonamid-matriksmetalloproteinase-inhibitorer

Country Status (22)

Country Link
EP (1) EP0901466B1 (enExample)
JP (1) JP2000511175A (enExample)
KR (1) KR20000011095A (enExample)
CN (1) CN1077885C (enExample)
AT (1) ATE207891T1 (enExample)
BG (1) BG63940B1 (enExample)
BR (1) BR9710841A (enExample)
CA (1) CA2253342A1 (enExample)
CZ (1) CZ294063B6 (enExample)
DE (1) DE69707865T2 (enExample)
DK (1) DK0901466T3 (enExample)
EA (1) EA001561B1 (enExample)
EE (1) EE03965B1 (enExample)
ES (1) ES2167733T3 (enExample)
IL (1) IL126832A0 (enExample)
NO (1) NO312510B1 (enExample)
NZ (1) NZ332711A (enExample)
PL (1) PL186416B1 (enExample)
PT (1) PT901466E (enExample)
SK (1) SK282863B6 (enExample)
WO (1) WO1997044315A1 (enExample)
ZA (1) ZA974223B (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0766665B1 (en) * 1994-06-22 1999-07-28 British Biotech Pharmaceuticals Limited Metalloproteinase inhibitors
US6124333A (en) * 1995-06-22 2000-09-26 British Biotech Pharmaceuticals Limited Metalloproteinase inhibitors
WO1998025597A2 (en) * 1996-12-09 1998-06-18 Warner-Lambert Company Method for treating and preventing heart failure and ventricular dilatation
JP2001507342A (ja) 1996-12-17 2001-06-05 ワーナー−ランバート・コンパニー 神経疾患の治療および創傷治癒を促進するためのマトリックスメタロプロテイナーゼ阻害剤の使用
SI0946166T1 (en) * 1996-12-17 2004-06-30 Warner-Lambert Company Llc Use of matrix metalloproteinase inhibitors for promoting wound healing
GB9706255D0 (en) 1997-03-26 1997-05-14 Smithkline Beecham Plc Novel compounds
DE19719621A1 (de) * 1997-05-09 1998-11-12 Hoechst Ag Sulfonylaminocarbonsäuren
PL338235A1 (en) 1997-07-22 2000-10-09 Shionogi & Co Preparation for treating or preventing glomerulopathic states
AU751701B2 (en) * 1997-12-23 2002-08-22 Warner-Lambert Company Ace inhibitor-MMP inhibitor combinations
US6410580B1 (en) 1998-02-04 2002-06-25 Novartis Ag Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases
IL137465A0 (en) * 1998-02-04 2001-07-24 Novartis Ag Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases
NZ505994A (en) * 1998-03-17 2003-10-31 Warner Lambert Co Statin-matrix metalloproteinase inhibitor combinations useful fro treating vascular diseases
EP0967201A1 (en) * 1998-05-20 1999-12-29 Roche Diagnostics GmbH Pharmaceutical agents containing sulfonamids as matrix metalloproteinase inhibitors
DE59903329D1 (en) * 1998-07-16 2002-12-12 Aventis Pharma Gmbh Phosphin- und phosphonsäurederivate als arzneimittel
CA2335062A1 (en) * 1998-07-21 2000-02-03 Thomas Michael Andrew Bocan Coadministration of acat and mmp inhibitors for the treatment of atherosclerotic lesions
DE19851184A1 (de) * 1998-11-06 2000-05-11 Aventis Pharma Gmbh N-Arylsulfonyl-aminosäure-omega-amide
US6858598B1 (en) 1998-12-23 2005-02-22 G. D. Searle & Co. Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
PL351374A1 (en) * 1999-04-19 2003-04-07 Shionogi & Co Sulfonamide derivatives having oxadiazole rings
GB9918684D0 (en) 1999-08-09 1999-10-13 Novartis Ag Organic compounds
JP3910446B2 (ja) 1999-11-26 2007-04-25 塩野義製薬株式会社 Npyy5拮抗剤
CA2423885A1 (en) * 2000-09-29 2003-03-27 Shionogi & Co., Ltd. Thiazole and oxazole derivatives
GB0103303D0 (en) 2001-02-09 2001-03-28 Novartis Ag Organic compounds
MXPA01013326A (es) 2001-02-14 2002-08-26 Warner Lambert Co Bifenil sulfonamidas utiles como inhibisdores de metaloproteinasa de matriz.
JP4219810B2 (ja) * 2001-10-26 2009-02-04 塩野義製薬株式会社 Mmp阻害作用を有するスルホンアミド誘導体
GB0314488D0 (en) * 2003-06-20 2003-07-23 Glaxo Group Ltd Therapeutically useful compounds
JP2007525406A (ja) * 2003-12-04 2007-09-06 ワイス ビアリールスルホンアミドおよびその使用方法
US8129406B2 (en) * 2004-03-22 2012-03-06 Southern Research Institute Nonpeptide inhibitors of matrix metalloproteinases
CN101279956B (zh) * 2008-04-25 2011-06-15 南昌大学 一种基质金属蛋白酶抑制剂及合成方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5506242A (en) * 1993-01-06 1996-04-09 Ciba-Geigy Corporation Arylsufonamido-substituted hydroxamic acids
EP0766665B1 (en) * 1994-06-22 1999-07-28 British Biotech Pharmaceuticals Limited Metalloproteinase inhibitors

Also Published As

Publication number Publication date
CN1077885C (zh) 2002-01-16
ZA974223B (en) 1997-12-10
BR9710841A (pt) 1999-08-17
PL329929A1 (en) 1999-04-26
JP2000511175A (ja) 2000-08-29
WO1997044315A1 (en) 1997-11-27
SK282863B6 (sk) 2002-12-03
DE69707865T2 (de) 2002-05-02
PL186416B1 (pl) 2004-01-30
CA2253342A1 (en) 1997-11-27
EP0901466B1 (en) 2001-10-31
BG102918A (en) 1999-09-30
NZ332711A (en) 2000-06-23
NO312510B1 (no) 2002-05-21
KR20000011095A (ko) 2000-02-25
BG63940B1 (bg) 2003-07-31
PT901466E (pt) 2002-04-29
ATE207891T1 (de) 2001-11-15
IL126832A0 (en) 1999-08-17
CN1219166A (zh) 1999-06-09
AU2680397A (en) 1997-12-09
SK157798A3 (en) 1999-04-13
NO985326L (no) 1999-01-14
DE69707865D1 (de) 2001-12-06
EA199800988A1 (ru) 1999-04-29
ES2167733T3 (es) 2002-05-16
AU713286B2 (en) 1999-11-25
HK1019585A1 (en) 2000-02-18
EE9800397A (et) 1999-06-15
CZ366898A3 (cs) 1999-02-17
CZ294063B6 (cs) 2004-09-15
EA001561B1 (ru) 2001-04-23
EE03965B1 (et) 2003-02-17
NO985326D0 (no) 1998-11-16
EP0901466A1 (en) 1999-03-17

Similar Documents

Publication Publication Date Title
ATE207891T1 (de) Biphenylsulfonamid matrix metalloproteinase inhibitoren
AU6894800A (en) Caspase inhibitors and uses thereof
UY25322A1 (es) Compuestos de tiourea y benzamida,composiciones y metodos para tratar y prevenir enfermedades inflamatorias y aterosclerosis
WO2003024448A3 (en) Inhibitors of histone deacetylase
ATE289590T1 (de) Beta-sulfonyl-hydroxamsäuren als matrix- metalloproteinaseinhibitoren
EP0931788A3 (en) Metalloprotease inhibitors
DK0705254T3 (da) Phenylheterocykliske forbindelser som cyclooxygenase-2-inhibitorer
EA200101085A1 (ru) Гидроксамовые кислоты, производные ароматических сульфонов, - ингибиторы металлопротеаз
EA200100804A1 (ru) Сульфоароматические производные гидроксамовой кислоты как ингибиторы металлопротеаз
DK0946166T3 (da) Anvendelse af matrixmetalloproteinaseinhibitorer til fremme af sårheling
PT1250340E (pt) Metodos e compostos para inibicao de mrp1
NZ333550A (en) Matrix metalloproteinase inhibitors for inhibiting the release of TNF
CA2266759A1 (en) 3-mercaptoacetylamino-1,5-substituted-2-oxo-azepan derivatives useful as inhibitors of matrix metalloproteinase
AU2001255646A1 (en) Method of inhibiting amyloid protein aggregation and imaging amyloid deposits using aminoindane derivatives
DE69736945D1 (de) Biphenylverbindungen sowie ihre anwendung als östrogene mittel
GR3032698T3 (en) Organic compounds
ATE282602T1 (de) Buttersäure matrix-metalloproteinase-inhibitoren
BR0214886A (pt) Fenilalquinos
AU5230898A (en) Metalloproteinase inhibitors
PT971714E (pt) Metodo utilizando inibidores ciclooxigenase-2 no tratamento e prevencao da demencia